GlassScriptPhysician profile
Adli Yakan
NPI 1417174699
$1,387.92
in general payments reported to CMS, 2019-2025
25 companies · $282 in 2025
The $282 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.30 · 2021: $152 · 2022: $177 · 2023: $239 · 2024: $513 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,017 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,017.04 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $193.50 | 2021-2025 | |
| Pfizer INC. | $136.13 | 2019-2025 | |
| Astellas Pharma US INC | $125.58 | 2021-2025 | Xtandi, Padcev |
| Gilead Sciences, INC. | $95.33 | 2021-2024 | Trodelvy |
| Glaxosmithkline, LLC. | $94.34 | 2024-2025 | Ojjaara, Blenrep |
| E.R. Squibb & Sons, L.L.C. | $86.11 | 2022-2025 | Opdivo, Krazati |
| Seagen INC. | $66.25 | 2021-2023 | Adcetris |
| Genentech USA, INC. | $62.21 | 2021-2023 | Tecentriq, Alecensa, Venclexta |
| Sumitomo Pharma America, INC. | $60.19 | 2023-2024 | Orgovyx |
| Servier Pharmaceuticals LLC | $55.13 | 2024-2025 | |
| Genzyme Corporation | $50.04 | 2022 | |
| Emd Serono, INC. | $43.80 | 2022 | |
| Celgene Corporation | $41.46 | 2023-2025 | Reblozyl |
| Tersera Therapeutics LLC | $37.83 | 2024 | Zoladex |
| Kite Pharma, INC. | $35.96 | 2024-2025 | Yescarta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $31.46 | 2023-2024 | Tecvayli, Talvey, Darzalex |
| Abbvie INC. | $30.12 | 2024 | |
| Eisai INC. | $26.60 | 2024 | |
| Daiichi Sankyo INC. | $21.03 | 2022 | |
| Exelixis INC. | $18.75 | 2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Array Biopharma INC | $16.83 | 2024 | Mektovi, Braftovi, Lorbrena |
| Amgen INC. | $15.40 | 2023 | Kyprolis, Blincyto |
| Pharmacyclics LLC, An Abbvie Company | $14.59 | 2023 | Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adli Yakan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.